EyePoint Pharmaceuticals ...

5.38
0.33 (6.53%)
At close: Apr 02, 2025, 3:59 PM
5.20
-3.26%
Pre-market: Apr 03, 2025, 08:00 AM EDT

EyePoint Pharmaceuticals Statistics

Share Statistics

EyePoint Pharmaceuticals has 68.73M shares outstanding. The number of shares has increased by 31.96% in one year.

Shares Outstanding 68.73M
Shares Change (YoY) 31.96%
Shares Change (QoQ) 0.7%
Owned by Institutions (%) 99.99%
Shares Floating 59.62M
Failed to Deliver (FTD) Shares 982
FTD / Avg. Volume 0.12%

Short Selling Information

The latest short interest is 10.58M, so 15.5% of the outstanding shares have been sold short.

Short Interest 10.58M
Short % of Shares Out 15.5%
Short % of Float 17.11%
Short Ratio (days to cover) 11.81

Valuation Ratios

The PE ratio is -3.2 and the forward PE ratio is -3.18. EyePoint Pharmaceuticals's PEG ratio is -0.12.

PE Ratio -3.2
Forward PE -3.18
PS Ratio 9.69
Forward PS 0.6
PB Ratio 1.25
P/FCF Ratio -3.22
PEG Ratio -0.12
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for EyePoint Pharmaceuticals.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 7.81, with a Debt / Equity ratio of 0.06.

Current Ratio 7.81
Quick Ratio 7.77
Debt / Equity 0.06
Debt / EBITDA -0.17
Debt / FCF -0.17
Interest Coverage -10418.14

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $262.26K
Profits Per Employee $-793.15K
Employee Count 165
Asset Turnover 0.1
Inventory Turnover 1.61

Taxes

Income Tax 90K
Effective Tax Rate -0.07%

Stock Price Statistics

The stock price has increased by -74.07% in the last 52 weeks. The beta is 1.42, so EyePoint Pharmaceuticals's price volatility has been higher than the market average.

Beta 1.42
52-Week Price Change -74.07%
50-Day Moving Average 6.67
200-Day Moving Average 8.37
Relative Strength Index (RSI) 35.79
Average Volume (20 Days) 818.37K

Income Statement

In the last 12 months, EyePoint Pharmaceuticals had revenue of 43.27M and earned -130.87M in profits. Earnings per share was -2.32.

Revenue 43.27M
Gross Profit 39.56M
Operating Income -145.85M
Net Income -130.87M
EBITDA -129.23M
EBIT -130.77M
Earnings Per Share (EPS) -2.32
Full Income Statement

Balance Sheet

The company has 99.7M in cash and 21.86M in debt, giving a net cash position of 77.85M.

Cash & Cash Equivalents 99.7M
Total Debt 21.86M
Net Cash 77.85M
Retained Earnings -873.02M
Total Assets 418.46M
Working Capital 334.26M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -126.23M and capital expenditures -4.05M, giving a free cash flow of -130.28M.

Operating Cash Flow -126.23M
Capital Expenditures -4.05M
Free Cash Flow -130.28M
FCF Per Share -2.31
Full Cash Flow Statement

Margins

Gross margin is 91.42%, with operating and profit margins of -337.06% and -302.43%.

Gross Margin 91.42%
Operating Margin -337.06%
Pretax Margin -302.22%
Profit Margin -302.43%
EBITDA Margin -298.63%
EBIT Margin -337.06%
FCF Margin -301.06%

Dividends & Yields

EYPT does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for EYPT is $29, which is 439% higher than the current price. The consensus rating is "Buy".

Price Target $29
Price Target Difference 439%
Analyst Consensus Buy
Analyst Count 8
Stock Forecasts

Stock Splits

The last stock split was on Dec 9, 2020. It was a backward split with a ratio of 1:10.

Last Split Date Dec 9, 2020
Split Type backward
Split Ratio 1:10

Scores

Altman Z-Score -0.3
Piotroski F-Score 3